Zhitong Finance App News, Yasheng Pharmaceutical (06855) announced that several of the company's clinical and preclinical research advances were selected for the 68th American Society of Hematology (ASH) annual meeting, involving the first third-generation BCR-ABL inhibitor approved for marketing in China, olevatinib (trade name: Nellick®), the first domestically produced original Bcl-2 inhibitor approved for marketing in China (trade name: Risentol®), PRC2/EED inhibitor APG-5918, and The four varieties of BTK degrading agent APG-3288 fully demonstrate the company's deep layout and global innovation strength in the field of hematologic oncology. It is worth noting that APG-5918 first published clinical data and received an oral report.
The annual ASH annual conference is one of the largest academic events in the field of hematology in the world, covering comprehensive research on the etiology and treatment of blood diseases. The 68th ASH Annual Meeting will be held from December 12, 2026 to December 15, 2026, local time in New Orleans, Louisiana, USA in a combination of offline and online formats.
At this ASH annual conference, APG-5918 will present its clinical data on the efficacy and safety of relapsed/refractory T-cell lymphoma (R/R TCL) in the form of an oral report for the first time. R/R TCL has strong disease heterogeneity. Some patients are resistant to existing chemotherapy and targeted treatments, clinical treatment options are limited, and there are significant unmet medical needs. As a novel EED inhibitor, APG-5918 has shown encouraging anti-tumor activity and manageable safety in early clinical studies, and is expected to provide a new epigenetic targeted treatment option for such patients with difficult to treat TCL.
At the same time, Yasheng Pharmaceutical will release data from multiple combined treatment studies with olevatinib and risatocla. Relevant studies cover myeloid and gonorrheal hematologic tumors, adults and children, and the entire course of the disease is difficult to treat at the beginning and recurrence. In patients with recurrent refractory acute myeloid leukemia (R/R AML) treated with Vinecla, triple therapy with risatocla combined with olevatinib showed positive efficacy. In the field of acute lymphocytic leukemia (ALL), the chemotherapeutic regimen of olevatinib combined with lisatocla is used in children with R/R Philly chromosome positive (Ph+) ALL, which can achieve deep remission and has the ability to penetrate the central nervous system; for newly diagnosed (ND) children with Ph+ ALL, the Orebatinib combination regimen also showed a high disease remission rate. Furthermore, updated data on olevatinib chemotherapy-free combination regimens in lymphoblast-phase chronic myeloid leukemia (CML-LBP) and Ph+ B-cell precursor acute lymphocytic leukemia (Ph+ BCP-ALL) will further validate the value of the new chemoreduction strategy in intractable lymphatic hematologic tumors.
In addition, the company will also disclose the collaborative anti-tumor effects of lisatocla in combination with olevatinib and APG-5918 in preclinical models of diffuse large B-cell lymphoma (DLBCL), respectively.